Shinichi Kageyama, MD., Ph,D.
Professor, Immuno-Gene Therapy, Mie University Graduate School of Medicine
2-174, Edobashi, Tsu, Mie, 514-8507
Phone +59-231-5187, Fax +59-231-5276
Profiles and Research Field
Dr. Kageyama has been working on cancer immunotherapy since 1998. As a medical oncologist and hematologist, he has been developing and conducting clinical trials. Dr. Kageyama and his colleges use their original cancer vaccine consisting of CHP-nanogel and tumor antigen. They developed CHP-HER2, CHP-MAGE-A4 and CHP-NY-ESO-1, and have been working on early clinical trials. Since 1995, collaborating with Takara Bio Inc., they have developed TCR-gene transduced T cell therapy. The clinical trials they have been studying are MAGE-A4 TCR-gene transduced cell adoptive transfer for esophageal cancer, WT1 TCR-gene therapy for AML and MDS, and NY-ESO-1 TCR-gene therapy for all diseases. They are now conducting phase 1/2 clinical trial of NY-ESO-1 TCR-T combined with novel cancer vaccine, NE-1, and CpG for soft tissue sarcoma.
- Kakimoto T, Matsumine A, Kageyama S, Asanuma K, Matsubara T, Nakamura T, Iino T, Ikeda H, Shiku H, Sudo A. Immunohistochemical expression and clinicopathological assessment of the cancer testis antigens NY-ESO-1 and MAGE-A4 in high-grade soft-tissue sarcoma. Oncol Lett. 17(4):3937-3943. 2019.
- Ueda S, Miyahara Y, Nagata Y, Sato E, Shiraishi T, Harada N, Ikeda H, Shiku H, Kageyama S. NY-ESO-1 antigen expression and immune response are associated with poor prognosis in MAGE-A4-vaccinated patients with esophageal or head/neck squamous cell carcinoma. Oncotarget. 9(89):35997-36011. 2018.
- Fujiwara-Kuroda A, Kato T, Abiko T, Tsuchikawa T, Kyogoku N, Ichinokawa M, Tanaka K, Noji T, Hida Y, Kaga K, Matsui Y, Ikeda H, Kageyama S, Shiku H, Hirano S. Prognostic value of MAGEA4 in primary lung cancer depends on subcellular localization and p53 status. Int J Oncol. 53(2):713-724. 2018.
- Wada M, Tsuchikawa T, Kyogoku N, Abiko T, Miyauchi K, Takeuchi S, Kuwatani T, Shichinohe T, Miyahara Y, Kageyama S, Ikeda H, Shiku H, Hirano S. Clinical Implications of CD4+CD25+Foxp3+Regulatory T Cell Frequencies After CHP-MAGE-A4 Cancer Vaccination. Anticancer Res. 38(3):1435-1444. 2018.
- Abiko T, Tsuchikawa T, Miyauchi K, Wada M, Kyogoku N, Shichinohe T, Miyahara Y, Kageyama S, Ikeda H, Shiku H, Hirano S. Serum immunoglobulin E response as a marker for unfavorable prognosis following cholesteryl pullulan-MAGE A4 vaccination. Oncol Lett. 15(3):3703-3711. 2018.
- Tawara I, Kageyama S, Miyahara Y, Fujiwara H, Nishida T, Akatsuka Y, Ikeda H, Tanimoto K, Terakura S, Murata M, Inaguma Y, Masuya M, Inoue N, Kidokoro T, Okamoto S, Tomura D, Chono H, Nukaya I, Mineno J, Naoe T, Emi N, Yasukawa M, Katayama N, Shiku H. Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS. Blood. 130(18):1985-1994. 2017.
- Tanaka Y, Ohishi K, Sawai T, Iwasaki H, Kageyama S, Masuya M, Matsumoto T, Tanigawa T, Wada H, Shiku H, Ito M, Katayama N. Attempt to Harvest a Sufficient Number of Mononuclear Cells in an Appropriate Blood Product Volume By Modification of the Default Apheresis Setting. Ther Apher Dial. 21(5):507-511. 2017.
- Kyogoku N, Ikeda H, Tsuchikawa T, Abiko T, Fujiwara A, Maki T, Yamamura Y, Ichinokawa M, Tanaka K, Imai N, Miyahara Y, Kageyama S, Shiku H, Hirano S. Time-dependent transition of the immunoglobulin G subclass and immunoglobulin E response in cancer patients vaccinated with cholesteryl pullulan-melanoma antigen gene-A4 nanogel. Oncol Lett. 12(6):4493-4504. 2016.
- Immunotherapy of cancer: an innovative treatment comes of age. (Edited by Yoshiyuki Yamaguchi), Chapter: Protein vaccine / Shinichi Kageyama, Tokyo, Springer, 2016.
- Miyauchi K, Tsuchikawa T, Wada M, Abiko T, Kyogoku N, Shichinohe T, Miyahara Y, Kageyama S, Ikeda H, Shiku H, Hirano S. Clinical relevance of antigen spreading pattern induced by CHP-MAGE-A4 cancer vaccination. Immunotherapy. 8(5):527-540, 2016.
- Guidance Development Review Committee; Working Group for Clinical Studies of Cancer Immunotherapy; Working Group for Effector Cell Therapy; Working Group for CMC/Non-clinical Studies; Working Group for Cancer Vaccines and Adjuvants; Working Group for Anti-immune Checkpoint Therapy and Comprehensive Cancer Immunotherapy; Biostatistics Subcommittee. 2015 Guidance on cancer immunotherapy development in early-phase clinical studies.
- Cancer Sci. 106(12):1761-1771, 2015. (corresponding author, Kageyama S)
- Kageyama S, Ikeda H, Miyahara Y, Imai N, Ishihara M, Saito K, Sugino S, Ueda S, Ishikawa T, Kokura S, Naota H, Ohishi K, Shiraishi T, Inoue N, Tanabe M, Kidokoro T, Yoshioka H, Tomura D, Nukaya I, Mineno J, Takesako K, Katayama N, Shiku H. Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer. Clin Cancer Res. 21(10):2268-2277, 2015.
- Saito T, Wada H, Yamasaki M, Miyata H, Nishikawa H, Sato E, Kageyama S, Shiku H, Mori M, Doki Y. High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine. Vaccine. 14;32(45):5901-5907, 2014.